Bio-Path Holdings, Inc. (BPTH )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol BPTH
- Company Bio-Path Holdings, Inc.
- Price $1.26
- Changes Percentage -15.44
- Change -0.23
- Day Low $1.16
- Day High $1.45
- Year High $12
- Year Low $0.59
- Market Cap $5,426,681
- Price Avg 50 EMA (D) $0.89
- Price Avg 200 EMA (D) $1.94
- Exchange NASDAQ
- Volume 3,699,680
- Average Volume 3,000,530
- Open $1.39
- Previous Close $1.49
- EPS -8.34
- PE -0.15
- Earnings Announcement 2025-03-06 05:00:00
- Shares Outstanding $4,306,890
Company brief: BIO-PATH HOLDINGS, INC. (BPTH )
- Healthcare
- Biotechnology
- Mr. Peter H. Nielsen MBA
- https://www.biopathholdings.com
- US
- N/A
- 03-04-2008
- US09057N3008
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.